OP \$165.00 402644

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM356439

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Security Interest in Intellectual Property Collateral at Reel/Frame No. 4931/0058

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Royal Bank of Canada		09/25/2015	bank: CANADA

RECEIVING PARTY DATA

Name:	Therakos, Inc.
Street Address:	5 Great Valley Parkway
City:	Malvern
State/Country:	PENNSYLVANIA
Postal Code:	19355
Entity Type:	CORPORATION: FLORIDA

PROPERTY NUMBERS Total: 6

Property Type	Number	Word Mark
Registration Number:	4026448	CELLEX
Registration Number:	4115195	THERAKOS
Registration Number:	4006506	UVADEX
Registration Number:	4074104	UVADEX
Registration Number:	3908397	UVAR
Registration Number:	3949903	UVAR XTS

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: ipdocket@lw.com

Correspondent Name: Latham & Watkins LLP

Address Line 1:650 Town Center Drive, Suite 2000Address Line 4:Costa Mesa, CALIFORNIA 92626

ATTORNEY DOCKET NUMBER:	045777-0011
NAME OF SUBMITTER:	Rhonda DeLeon
SIGNATURE:	/Rhonda DeLeon/
DATE SIGNED:	09/25/2015

Total Attachments: 5 source=Therakos IP Release (First Lien) (Executed)#page1.tif source=Therakos IP Release (First Lien) (Executed)#page2.tif source=Therakos IP Release (First Lien) (Executed)#page3.tif source=Therakos IP Release (First Lien) (Executed)#page4.tif source=Therakos IP Release (First Lien) (Executed)#page5.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL, dated as of September 25, 2015 (this "Release"), is made by Royal Bank of Canada, as collateral agent (in such capacity, the "Collateral Agent"), pursuant to the First Lien Credit Agreement, dated as of December 27, 2012, among TGG Medical Solutions, Inc., a Delaware corporation ("TGG Solutions"), TGG Medical Transitory, Inc., a Delaware corporation ("TGG Transitory"), the Collateral Agent and the other Lenders and Agents party thereto (the "Initial Credit Agreement"). Capitalized terms not otherwise defined herein have the meaning assigned to them in the Credit Agreement (as defined below).

WITNESSETH

WHEREAS, upon consummation of the Therakos Merger, Therakos, Inc., a Florida corporation ("<u>Therakos</u>" and, together with TGG Solutions and TGG Transitory, each a "<u>Grantor</u>" and collectively the "<u>Grantors</u>"), succeeded to the interest of TGG Transitory and became a party to the Amended and Restated First Lien Credit Agreement, dated as of January 18, 2013, among Therakos, TGG Solutions, the Collateral Agent and the other Lenders and Agents party thereto (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and, together with the Initial Credit Agreement, the "<u>Credit</u> Agreement");

WHEREAS, pursuant to the Credit Agreement, the Grantors executed the Intellectual Property Security Agreement, dated as of December 27, 2012 (the "Intellectual Property Security Agreement") and recorded with the U.S. Patent and Trademark Office on December 28, 2012 at Reel/Frame Nos. 29549/0074 and 4931/0058, pursuant to which the Grantors granted to the Collateral Agent for the ratable benefit of the Secured Parties a security interest in the Grantors' right, title and interest in, to and under the IP Collateral (as defined in the Intellectual Property Security Agreement);

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent agrees as follows:

The Collateral Agent hereby TERMINATES, without recourse, representation or warranty of any kind or nature, and RELEASES, without recourse, representation or warranty of any kind or nature its security interest in the IP Collateral, including the patents, patent applications, trademark registrations, and trademark applications set forth in Schedule A, attached hereto and incorporated herein by reference.

The Collateral Agent agrees to provide the Grantors with any additional authorization reasonably necessary to effect the release of the Collateral Agent's security interest in the IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be doly executed and delivered by its duly authorized officer as of the date first written above.

ROYAL BANK OF CANADA,

as Collateral Agent

By: Name:

Title:

Susan Khokher Manager, Agency

REEL: 005631 FRAME: 0149

SCHEDULE A TO RELEASE OF SECURITY INTEREST IN TRADEMARK COLLATERAL

PATENTS

Registered Patents:

Patent	Registration No.	Registration Date	Owner
Securing system for centrifuge chamber	5308309	5/3/1994	Therakos, Inc.
Photoactivation light array	5569928	10/29/1996	Therakos, Inc.
Ultraviolet light chamber	5459322	10/17/1995	Therakos, Inc.
Photopheresis treatment of leukocytes	5984887	11/16/1999	Therakos, Inc.
Integrated cassette for controlling fluid	6491656	12/10/2002	Therakos, Inc.
having an integral filter			
Apparatus for pumping fluid at a steady flow rate	5921951	7/13/1999	Therakos, Inc.
Blood product irradiation device	5951509	9/14/1999	Therakos, Inc.
incorporating agitation			
Contaminant detector	6069687	5/30/2000	Therakos, Inc.
Method for removal of psoralens from	6228995	5/8/2001	Therakos, Inc.
biological fluids			
Treatment of inflammatory disorders of	5985914	11/16/1999	Therakos, Inc.
the bowel and urinary bladder			
Method and system for determining an	6219584	4/17/2001	Therakos, Inc.
effective amount of light energy to			
delivery to fluids having targets for the			
light energy			
Uninterrupted flow pump apparatus and method	8153083	4/10/2012	Therakos, Inc.
Uninterrupted flow pump apparatus and method	7534616	5/19/2009	Therakos, Inc.
Uninterrupted flow pump apparatus and	6495366	12/17/2002	Therakos, Inc.
method			
Low extracorporeal volume treatment	6793643	9/21/2004	Therakos, Inc.
system			,
Method and apparatus for the continuous	7186230	3/6/2007	Therakos, Inc.
separation of biological fluids into			
components			
Apparatus for the continuous separation	7211037	5/1/2007	Therakos, Inc.
of biological fluids into components and			
method of using same			

NY\7302594.4 **TRADEMARK**

REEL: 005631 FRAME: 0150

Patent	Registration No.	Registration Date	Owner
Method for collecting a desired blood	7479123	1/20/2009	Therakos, Inc.
component and performing a			
photopheresis treatment			
Apparatus for the continuous separation	7914477	3/29/2011	Therakos, Inc.
of biological fluids into components and			
method of using same			
Apparatus for the continuous separation	7503889	3/17/2009	Therakos, Inc.
of biological fluids into components and			
method of using same			
Method for collecting a desired blood	7850634	12/14/2010	Therakos, Inc.
component and performing a			
photopheresis treatment			
Control system for driving fluids through	7465285	12/16/2008	Therakos, Inc.
an extracorporeal blood circuit	- / - / - 0 0	444	
Method and apparatus for collecting a	7476209	1/13/2009	Therakos, Inc.
blood component and performing a			
photopheresis treatment	00	11170011	
Phototherapy compositions and methods	8057785	11/15/2011	Therakos, Inc.
Uninterrupted flow pump apparatus and	8722422	5/13/2014	Therakos, Inc.
method			
Phototherapy compositions and methods	8481008	7/9/2013	Therakos, Inc.

Patent Applications:

Patent	Application No.	Application Date	Owner
Processing Blood	12/628303	12/1/2009	Therakos, Inc.
	Published No. US-2010-		
	0210989-A1		
Method for ex-vivo	12/781451	5/17/2010	Therakos, Inc.
expansion of regulatory T	Published No. US-		
cells with enhanced	2010-0291117-A1		
suppressive function for			
clinical application in			
immune mediated diseases			
Use of apoptotic cells ex	11/579319	7/14/2008	Therakos, Inc.
vivo to generate regulatory	Published No. US-		
T cells	2008-0267934-A1		

METHOD FOR	12/795,308	6/07/2010	Therakos, Inc.
COLLECTING A			
DESIRED BLOOD			
COMPONENT AND	Published No. US		
PERFORMING A	2010-0298752 A1		
PHOTOPHERESIS			
TREATMENT			

TRADEMARKS

Registered Trademarks:

Trademark	Registration No.	Registration Date	Owner
CELLEX	4026448	9/13/2011	Therakos, Inc.
THERAKOS	4115195	3/20/2012	Therakos, Inc.
UVADEX	4006506	8/2/2011	Therakos, Inc.
UVADEX	4074104	12/20/2011	Therakos, Inc.
UVAR	3908397	1/18/2011	Therakos, Inc.
UVAR XTS	3949903	4/26/2011	Therakos, Inc.

Trademark Applications: NONE

COPYRIGHTS

None.

NY\7302594.4

RECORDED: 09/25/2015

REEL: 005631 FRAME: 0152